Invention Grant
- Patent Title: Decreasing potential iatrogenic risks associated with influenza vaccines
- Patent Title (中): 降低与流感疫苗相关的潜在医源性风险
-
Application No.: US13740100Application Date: 2013-01-11
-
Publication No.: US09358280B2Publication Date: 2016-06-07
- Inventor: Jens-Peter Gregersen
- Applicant: Novartis AG
- Applicant Address: CH Basel
- Assignee: Novartis AG
- Current Assignee: Novartis AG
- Current Assignee Address: CH Basel
- Agency: Morrison & Foerster LLP
- Priority: EP04255471 20040909
- Main IPC: C12Q1/70
- IPC: C12Q1/70 ; A61K39/145 ; C12N7/00 ; A61K39/12

Abstract:
Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realized that the conditions used for influenza virus culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.
Public/Granted literature
- US20130129782A1 DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES Public/Granted day:2013-05-23
Information query